Navigation Links
Pivotal Registration Trial of OPAXIO Maintenance Therapy in First-Line Ovarian Cancer Reaches Enrollment Milestone of 600 patients, Cell Therapeutics and the Gynecologic Oncology Group Discuss Potential for Early Interim Analysis
Date:9/21/2009

SEATTLE, Sept. 21 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) announced today that it will re-focus its resources on the approval of OPAXIO(TM) for its potential superiority indication in maintenance therapy for ovarian cancer. The Gynecologic Oncology Group (GOG) is conducting an ongoing phase III trial that evaluates the use of 12 months of OPAXIO therapy versus an untreated control arm. To date, 600 patients have been enrolled in this trial. CTI has discussed with the GOG, several strategies for conducting an interim analysis which could potentially result in an earlier registration. In addition, given the encouraging results of treatment of advanced esophageal cancer with OPAXIO to be reported at the upcoming International Society of Gastrointestinal Oncology Annual Meeting, CTI plans on meeting with the Food and Drug Administration (FDA) to discuss an additional registration study utilizing OPAXIO as a radiation sensitizer in the treatment of advanced esophageal cancer.

CTI has notified the European Medicines Agency (EMEA) of its decision to withdraw its Marketing Authorization Application (MAA) for a non-inferiority indication in non-small cell lung cancer (NSCLC).

"Given that we have reached a milestone in the ovarian cancer trial enrollment coupled with the reservations the Committee for Medicinal Products for Human Use (CHMP) expressed about the control arm activity in the NSCL cancer study we believe it makes best sense for CTI to focus its efforts with OPAXIO on superiority applications like the first-line ovarian cancer trial as well as the exciting new potential application as a radiation sensitizer," noted Craig W. Philips, President of CTI. "Both of these studies would be landmark trials and first in class for this novel bioengineered taxane. We look forward to continuing to work with the GOG and ultimately the FDA on a registr
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
4. Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
5. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
6. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
7. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
8. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
9. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
10. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
11. Arbios Provides Clinical Strategy for SEPET(TM) Pivotal Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)...  Hologic, Inc. (Hologic or the Company) (NASDAQ: ... and supplier of premium diagnostics, medical imaging systems ... the healthcare needs of women, today announced that ... clinical practice comparing breast cancer screening with Hologic,s ... mammography alone showed a significant reduction in recall ...
(Date:5/23/2013)... 23, 2013  BioElectronics Corporation (OTC Pink: BIEL), the ... on the FDA panel meeting for non-thermal shortwave diathermy: ... Pulsed Shortwave Therapy Meeting was held on May 21, ... The focus of the meeting was very narrow, in ... solely on the application of non-thermal shortwave diathermy for ...
(Date:5/23/2013)... YORK , May 23, 2013  Intercept Pharmaceuticals, ... stage biopharmaceutical company focused on the development and commercialization ... diseases, such as primary biliary cirrhosis, today announced that ... Chief Executive Officer, will present at the Deutsche Bank ... Boston on Wednesday, May 29, 2013 at ...
Breaking Medicine Technology:First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 2First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 3First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 4BioElectronics and Pulsed Shortwave Therapy Make Progress 2
... Significant Improvement in Cognitive Performance and Global Clinical Status ... ... 30 Forest Laboratories, Inc.,(NYSE: FRX ) presented today positive ... at the 2008,Alzheimer,s Association International Conference on Alzheimer,s Disease,(ICAD). The study ...
... 30 Wound Care Innovations, LLC,a subsidiary of ... today an evidence based study with a NE ... wound care collagen,product, CellerateRx(R), on diabetic venous ulcers. ... Control and Prevention, diabetes now,affects nearly 24 million ...
Cached Medicine Technology:New Data Highlight Positive Results of Namenda(R) (memantine HCl) Once-Daily Extended-Release Formulation 2New Data Highlight Positive Results of Namenda(R) (memantine HCl) Once-Daily Extended-Release Formulation 3New Data Highlight Positive Results of Namenda(R) (memantine HCl) Once-Daily Extended-Release Formulation 4Wound Management Technologies, Inc. Announces Agreement for Evidence Based Study for Diabetic Venous Ulcers 2
(Date:5/23/2013)... CA (PRWEB) May 23, 2013 EnvirOasis, ... the contractor and ESCO market is pleased to announce ... Consortium (DLC) Listed LED products. EnvirOasis has been ... fixtures and retrofit kits and has recently brought ... LED (Light Emitting Diode) is energy efficient lighting ...
(Date:5/23/2013)... May 23 (HealthDay News) -- The sensation of itching ... traced back to a small molecule released in the ... mice. Researchers say this molecule, known as natriuretic ... the central nervous system. Ultimately, this signal is experienced ... and mice are similar, the researchers concluded that a ...
(Date:5/23/2013)... HealthDay Reporter , , THURSDAY, May 23 (HealthDay News) ... sharply, especially among Hispanic teens, according to a new government ... 15 to 19 dropped by nearly one half from 1991 ... teens to 31 births for every 1,000. From 2007 ... 25 percent, from 41.5 to about 31. During that ...
(Date:5/23/2013)... A shortage of a critical tuberculosis drug has hampered ... to contain the spread of the highly infectious lung ... was first used in 1951 and is one of ... first-line treatment for tuberculosis (TB). Patients must take the ... U.S. Centers for Disease Control and Prevention. However, ...
(Date:5/23/2013)... U.S. scientists have used virus isolated from a person ... whether the virus could infect and be transmitted between ... in influenza research, and efficient transmission of influenza virus ... the same process might occur in people. The research ... Allergy and Infectious Diseases, part of the National Institutes ...
Breaking Medicine News(10 mins):Health News:EnvirOasis Lighting Announces Energy Star and Design Lights Consortium LED Products 2Health News:Got an Itch? Mouse Study May Help Explain Why 2Health News:U.S. Teen Birth Rate Plummets: Report 2Health News:U.S. Teen Birth Rate Plummets: Report 3Health News:Shortage of Key Drug Hampering U.S. Efforts to Control TB: Report 2Health News:Ferrets, pigs susceptible to H7N9 avian influenza virus 2
... the No. 1 line-item cost of Medicare reimbursement and affects ... which can have devastating effects on the eye, affect 42 ... 80, and 68 percent of the population over the age ... University of Missouri professor has identified an important step in ...
... As millions of emails by,faithful Christians circulate around ... weeping image of Jesus Christ at Florida Hospital,s ... an explanation,today: "Jesus was weeping at the deplorable ... billion-dollar religious hospital,operation run by millionaire executives that ...
... effectiveness , , THURSDAY, April 17 (HealthDay News) -- The ... cells to their more plastic youthful condition in animal ... a possible new explanation for the antidepressant activity of ... it could be used to treat other conditions caused ...
... Dr. Thomas Gamba of Philadelphia to continue PDA,s efforts to improve ... ... Pennsylvania Dental,Association (PDA) recently installed Dr. Thomas W. Gamba of Philadelphia as,its ... improving patient access to oral health services will continue,to be a major ...
... MD, DrPH, Anna Cheskis Gelman and Murray Charles Gelman ... the Mailman School of Public Health and professor of ... 2008 Distinguished Investigator Award from NARSAD, the world,s leading ... Susser was selected for a study on famine and ...
... Celebrate Exemplary Nurses Who Support Chicagoland,s Medically ... when Sally Lemke lost,her nursing job providing prenatal care ... felt like a super star. That,s because the week,before ... her commitment and,passion for community health nursing and named ...
Cached Medicine News:Health News:MU researchers find clue to cataract formation 2Health News:Weeping Image of Jesus at Florida Hospital Explained 2Health News:Prozac Makes Old Brain Cells Young 2Health News:Prozac Makes Old Brain Cells Young 3Health News:New Pennsylvania Dental Association President Will Focus on Improving Access to Care 2Health News:New Pennsylvania Dental Association President Will Focus on Improving Access to Care 3Health News:Ezra Susser, MD, DrPH, receives Distinguished Investigator Award from NARSAD 2Health News:Chicagoland Super Star Community and Public Health Nurses - Now Is Your Chance to Win $25,000 2Health News:Chicagoland Super Star Community and Public Health Nurses - Now Is Your Chance to Win $25,000 3
... the world leader in peel-away introducers. ... for permanent pacemaker and defibrillator lead ... implantation, and for temporary pacemaker insertions. ... Medical Peel-Away introducers includes the Di-Lock™ ...
The RX HERCULINK® PLUS Biliary Stent System is Guidant's high performance .014" guide wire compatible system. It is available in stent diameters of 4.0-6.5mm for the 12mm stent length and 4.0-7.0...
... Supreme and Response catheters comprise the ... available for electrophysiology procedures. Their advanced ... for superior torque response with a ... curves and French sizes, Supreme and ...
... Supreme and Response catheters comprise the ... available for electrophysiology procedures. Their advanced ... for superior torque response with a ... curves and French sizes, Supreme and ...
Medicine Products: